0000930413-19-003028.txt : 20191213 0000930413-19-003028.hdr.sgml : 20191213 20191213164450 ACCESSION NUMBER: 0000930413-19-003028 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20191211 FILED AS OF DATE: 20191213 DATE AS OF CHANGE: 20191213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YANCOPOULOS GEORGE CENTRAL INDEX KEY: 0001226690 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 191285089 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 ownership.xml X0306 4 2019-12-11 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001226690 YANCOPOULOS GEORGE 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 1 0 0 President and CSO Common Stock 2019-11-18 5 G 0 E 325986 0.00 A 325986 D Common Stock 2019-12-12 4 M 0 95295 21.25 A 421281 D Common Stock 2019-12-12 4 F 0 49405 377.16 D 371876 D Common Stock 2019-12-12 4 M 0 150000 21.25 A 521876 D Common Stock 2019-12-12 4 F 0 77767 377.16 D 444109 D Common Stock 2019-08-05 5 G 0 E 75036 0.00 D 0 I by 2017 GRAT Common Stock 2019-02-19 5 G 0 E 150722 0.00 D 249278 I by 2018 GRAT Common Stock 2019-06-13 5 G 0 E 500000 0.00 A 500000 I by 2019 GRAT Common Stock 2019-02-19 5 G 0 E 150722 0.00 A 753316 I by Trust Common Stock 2019-06-13 5 G 0 E 500000 0.00 D 253316 I by Trust Common Stock 2019-08-05 5 G 0 E 75036 0.00 A 328352 I by Trust Common Stock 2019-11-14 5 G 0 E 2366 0.00 D 325989 I by Trust Common Stock 2019-11-18 5 G 0 E 325986 0.00 D 0 I by Trust Common Stock 5791 I By 401(k) Plan Class A Stock 2019-11-18 5 G 0 E 23367 0.00 A Common Stock 23367 23367 D Class A Stock 2019-11-18 5 G 0 E 23367 0.00 D Common Stock 23367 0 I By Trust Class A Stock Common Stock 5383 5383 I By Son Class A Stock Common Stock 14000 14000 I By Daughter Non-Qualified Stock Option (right to buy) 21.25 2019-12-12 4 M 0 95295 0.00 D 2019-12-18 Common Stock 95295 150000 D Non-Qualified Stock Option (right to buy) 21.25 2019-12-12 4 M 0 150000 0.00 D 2019-12-18 Common Stock 150000 0 D Non-Qualified Stock Option (right to buy) 372.46 2019-12-11 4 A 0 81278 0.00 A 2029-12-11 Common Stock 81278 81278 D Performance Stock Units 2019-12-11 4 A 0 25155 0.00 A Common Stock 25155 25155 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder. These shares of Class A Stock are presently convertible and such conversion feature does not expire. These shares of Class A Stock are held in custody for the benefit of the reporting person's child. The stock option award (combined incentive stock option and non-qualified stock option) vested in four equal annual installments, commencing one year after the date of grant. The option became exercisable on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012. The stock option award vests in four equal annual installments, commencing one year after the date of grant. Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. /s/ George Yancopoulos 2019-12-13 EX-24 2 c94730_ex24.htm

Exhibit 24

POWER OF ATTORNEY

 

Know all by these presents that the undersigned hereby constitutes and appoints each of Leonard S. Schleifer, Robert E. Landry, Joseph J. LaRosa, Richard Gluckselig, Beverly Dubs, and Amanda Souza, signing singly, as the undersigned’s true and lawful attorney-in-fact to:

 

(1)execute for and on behalf of the undersigned, in the undersigned’s capacity as a director or officer of Regeneron Pharmaceuticals, Inc. (the “Company”), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;

 

(2)do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

 

(3)take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by the undersigned, it being understood that the documents executed by such attorney-in-act on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of April, 2019.

 

 

/s/ George Yancopoulos

George D. Yancopoulos, M.D., Ph.D.